ALK and non-small cell lung carcinoma: Among the ALK-targeted tyrosine kinase inhibitors (TKIs), Enshatinib is approved as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring ALK-positive mutations.